ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : -20 مورد

Composite Assessment of Index Lesion Severity for Mycosis Fungoides and Sezary Syndrome

Composite Assessment of Index Lesion Severity for Mycosis Fungoides and Sezary Syndrome
Clinical sign and degree or size (scale of 0 to 8) Index lesion
1 2 3 4 5
Erythema          
Scaling          
Plaque elevation          
Hypo- or hyperpigmentation          
Lesion size*          
Subtotal:          
Total (sum of subtotals):  
Composite Assessment of Index Lesion Severity cannot be used as skin assessment in global response score. Suggestions for improvement include using actual size of lesion versus categorical score for size and eliminating pigmentation as a clinical parameter.
* Lesion size (cm2): 0: no measurable area; 1: >0 to ≤4; 2: >4 to ≤10; 3: >10 to ≤16; 4: >16 to ≤25; 5: >25 to ≤35; 6: >35 to ≤45; 7: >45 to ≤55; 8: >55 to ≤70; 9: >70 to ≤90; 10: >90 to ≤110; 11: >110 to ≤130; 12: >130 to ≤155; 13: >155 to ≤180; 14: >180 to ≤210; 15: >210 to ≤240; 16: >240 to ≤270; 17: >270 to ≤300; 18: >300.
From: Olsen EA, Whittaker S, Kim YH, et al. Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol; 29(18), 2011:2598-2607. Reprinted with permission. Copyright © 2011 American Society of Clinical Oncology. All rights reserved.
Graphic 83962 Version 1.0